Cited by 336Alzheimer's disease research and treatmentsBarrier Structure and Function StudiesCerebrospinal fluid and hydrocephalus

Clearing amyloid through the blood-brain barrier

Open access
Zlokovic, Berislav V.·2004·Journal of Neurochemistry

Abstract

According to the amyloid hypothesis, accumulation of amyloid beta-peptide (A beta) in the brain is the primary pathogenic event in Alzheimer's disease (AD). Recent evidence indicates that A beta within the intravascular space is linked to A beta deposited in the brain suggesting that transport of A beta between the brain, blood and cerebrospinal fluid, and across the blood-brain barrier, regulates brain A beta. Thus, understanding A beta exchanges between brain and blood, and vice versa, and developing transport-based systemic A beta-lowering strategies may provide new important insights into pathogenesis and therapeutic control of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2004.02385.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zlokovic, B. V.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2004-04-13
Volume
89
Issue
4
Pages
807-811
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2068631553
Cited by
336
References
34
Citations by year
2026: 3 · 2025: 8 · 2024: 5 · 2023: 8 · 2022: 1 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 11 · 2017: 16 · 2016: 17 · 2015: 11 · 2014: 20 · 2013: 21 · 2012: 22
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p01ag016223-04)
  • National Institute on Aging (AG16223)
  • National Institute of Neurological Disorders and Stroke (NS34467)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
amyloid-beta, blood-brain barrier, Alzheimer's disease, cerebrospinal fluid, amyloid hypothesis
MeSH terms
Receptor for Advanced Glycation End Products, Alzheimer Disease, Amyloid, Animals, Blood-Brain Barrier, Brain, Humans, Receptors, Immunologic, Amyloid beta-Peptides, LDL-Receptor Related Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review